BRAF and colorectal carcinoma: In a phase Ib dose-escalation study, 28 refractory BRAF-mutated CRC patients were included in two arms: encorafenib and cetuximab vs. encorafenib, cetuximab and alpelisib, an inhibitor of alpha subunit of PI3K.